Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Prestige Consumer Healthcare (PBH) EBITDA Margin (2016 - 2025)

Prestige Consumer Healthcare has reported EBITDA Margin over the past 16 years, most recently at 16.96% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 63.0% year-over-year to 16.96%; the TTM value through Dec 2025 reached 17.8%, down 29.0%, while the annual FY2025 figure was 18.58%, 24.0% up from the prior year.
  • EBITDA Margin for Q4 2025 was 16.96% at Prestige Consumer Healthcare, up from 15.64% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 21.4% in Q4 2023 and troughed at 84.87% in Q1 2023.
  • A 5-year average of 12.97% and a median of 17.57% in 2025 define the central range for EBITDA Margin.
  • Biggest five-year swings in EBITDA Margin: crashed -10595bps in 2023 and later soared 10058bps in 2024.
  • Year by year, EBITDA Margin stood at 18.74% in 2021, then rose by 14bps to 21.39% in 2022, then rose by 0bps to 21.4% in 2023, then dropped by -24bps to 16.33% in 2024, then grew by 4bps to 16.96% in 2025.
  • Business Quant data shows EBITDA Margin for PBH at 16.96% in Q4 2025, 15.64% in Q3 2025, and 21.19% in Q2 2025.